Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.19.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Operating activities    
Net loss $ (13,677,147) $ (9,890,319)
Adjustments to reconcile net loss provided by (used in) operating activities:    
Depreciation and amortization 2,203,423 2,262,570
Impairment of intangible assets 1,449,121 1,701,875
Stock-based compensation 1,123,402 851,255
Deferred taxes 18,870 23,764
Amortization of inventory fair value associated with acquisition of TRx and Avadel's pediatric products 40,240 177,238
Non-cash interest expense 0 351,566
Change in fair value of warrant liability and unit purchase option liability 28,668 19,333
Change in fair value of contingent consideration (811,948) 276,008
Changes in assets and liabilities:    
Accounts receivable, net 297,267 (373,299)
Other receivables 5,326,000 339,221
Inventory, net 452,931 (617,619)
Prepaid expenses and other assets 664,454 318,771
Escrowed cash receivable 0 (5,287)
Accounts payable (666) 1,640,959
Income taxes payable (639,784) (88,100)
Accrued expenses and other liabilities (6,313,686) 2,397,968
Net cash used in operating activities (9,838,855) (614,096)
Investing activities    
Acquisition of business 0 (1)
Purchase of property and equipment (256,926) (25,931)
Net cash used in investing activities (256,926) (25,932)
Financing activities    
Proceeds from exercise of stock options and warrants 256,816 390,473
Proceeds from sales of common stock under employee stock purchase plan 127,537 8,400
Restricted stock units withheld for taxes (18,057) 0
Proceeds from underwritten public offering, net 8,975,960 0
Payment of contingent consideration (379,255) 0
Payment of long-term debt (48,684) 0
Net cash provided by financing activities 8,914,317 398,873
Decrease in cash, cash equivalents and restricted cash (1,181,464) (241,155)
Cash, cash equivalents, and restricted cash at beginning of period 10,746,756 2,605,499
Cash, cash equivalents, and restricted cash at end of period 9,565,292 2,364,344
Supplemental disclosures of cash flow information    
Cash paid for interest 525,000 0
Cash paid for taxes 852,025 0
Supplemental disclosures of non-cash activities    
Leased asset obtained in exchange for new operating lease liability 743,025  
Debt assumed in Avadel Pediatric Products acquisition 0 (15,075,000)
Cash and cash equivalents 9,386,865 2,179,775
Restricted cash, current 26,265 9,527
Restricted cash, non-current $ 152,162 $ 175,042